Jazz Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes products for neurology and psychiatry primarily in the United States.
The company’s late-stage product candidate comprises JZP-6, which has completed two Phase III pivotal clinical trials, for the treatment of fibromyalgia.
JZP-7, a transdermal gel formulation of ropinirole for the treatment of restless legs syndrome.
In addition, the company is developing oral tablet forms for sodium oxybate. Jazz Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Palo Alto, California.
http://stockreads.com/Stock-Newsletter.aspx?id=42159#ixzz1Fph8Gzis
The company’s late-stage product candidate comprises JZP-6, which has completed two Phase III pivotal clinical trials, for the treatment of fibromyalgia.
JZP-7, a transdermal gel formulation of ropinirole for the treatment of restless legs syndrome.
In addition, the company is developing oral tablet forms for sodium oxybate. Jazz Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Palo Alto, California.
http://stockreads.com/Stock-Newsletter.aspx?id=42159#ixzz1Fph8Gzis
No comments:
Post a Comment